

# PAPER I

---

Circulating T cells derived from patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex

---

**CIRCULATING T CELLS IN PATIENTS WITH UNTREATED ACUTE MYELOGENOUS  
LEUKEMIA ARE HETEROGENEOUS AND CAN BE ACTIVATED THROUGH THE  
CD3/TCR COMPLEX**

Elisabeth Ersvaer <sup>1</sup>, Peter Hampson <sup>3</sup>, Øystein Wendelbo <sup>1,2</sup>, Janet M Lord <sup>3</sup>, Bjørn Tore Gjertsen <sup>1</sup>,  
Øystein Bruserud <sup>1</sup>

<sup>1</sup>Institute of Medicine and <sup>2</sup>Division for Infectious Diseases; University of Bergen and Haukeland  
University Hospital, Bergen, Norway.<sup>3</sup> MRC Centre for Immune Regulation, University of  
Birmingham, Birmingham, United Kingdom.

Short title: T cells in AML.

Corresponding author:

Elisabeth Ersvær, Section for Hematology, Institute of Medicine, The University of Bergen,

N-5021 Bergen, Norway.

Phone + 47 55 97 50 00      Fax + 47 55 97 29 50

E-mail: [elisabeth.ersvar@med.uib.no](mailto:elisabeth.ersvar@med.uib.no)

**Objectives.** T lymphocyte defects may contribute to the immune insufficiency seen in acute myelogenous leukemia (AML). We therefore characterized the T cell system for untreated AML patients.

**Methods.** T lymphocyte subsets were analyzed by flow cytometry for 45 AML patients. The *in vitro* interferon- $\gamma$  (IFN $\gamma$ ) release in response to stimulation with anti-CD3 plus anti-CD28 in the presence of autologous AML cells was examined for 31 patients.

**Results.** The majority of circulating lymphocytes were CD3<sup>+</sup> T cells, and CD19<sup>+</sup> B cells usually constituted <10% of the lymphocytes. Most T cells expressed the  $\alpha\beta$  T cell receptor (TCR $\alpha\beta$ <sup>+</sup>), and only a minority of the cells was TCR $\gamma\delta$ <sup>+</sup>. Both CD4<sup>+</sup> and CD8<sup>+</sup> T cells were detected, the CD4:CD8 ratio showed a wide variation but was generally >1.0. The majority of CD4<sup>+</sup> and CD8<sup>+</sup> T cells were CD45RA<sup>+</sup> cells. The T cells could be stimulated to release IFN $\gamma$  in response to anti-CD3 plus anti-CD28 ligation even in the presence of excess autologous AML blasts, and for a subset of patients (6 of 27) these IFN $\gamma$  levels could be further increased by the novel protein kinase C (PKC) agonist PEP005.

**Conclusions.** Circulating T cells in patients with untreated AML are mainly CD4<sup>+</sup> or CD8<sup>+</sup> TCR $\alpha\beta$ <sup>+</sup>; both CD45RA<sup>+</sup> and CD45R0<sup>+</sup> can be detected, and these cells can be activated through the CD3/TCR complex even in the presence of excess AML cells. For a subset of patients T cell responsiveness can be further increased by targeting PKC and these data therefore suggest that T cell function is not inhibited in AML patients.

Key words: cytopenia – T lymphocytes – chemotherapy – cytokines – AML